Substances that lower the levels of certain LIPIDS in the BLOOD. They are used to treat HYPERLIPIDEMIAS.
A fibric acid derivative used in the treatment of HYPERLIPOPROTEINEMIA TYPE III and severe HYPERTRIGLYCERIDEMIA. (From Martindale, The Extra Pharmacopoeia, 30th ed, p986)
Electron-dense cytoplasmic particles bounded by a single membrane, such as PEROXISOMES; GLYOXYSOMES; and glycosomes.
A large lobed glandular organ in the abdomen of vertebrates that is responsible for detoxification, metabolism, synthesis and storage of various substances.
An antilipemic agent which reduces both CHOLESTEROL and TRIGLYCERIDES in the blood.
An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES. It decreases LOW DENSITY LIPOPROTEINS and increases HIGH DENSITY LIPOPROTEINS.
An antilipemic agent that is the biologically active metabolite of CLOFIBRATE.
Conditions with excess LIPIDS in the blood.
Compounds that either share the structure of fibric acid in their molecular arrangement or are considered variants of the fibric acid structure.
A peroxisome proliferator that is used experimentally to promote liver tumors. It has been used as an antihyperlipoproteinemic agent.
Triglycerides are the most common type of fat in the body, stored in fat cells and used as energy; they are measured in blood tests to assess heart disease risk, with high levels often resulting from dietary habits, obesity, physical inactivity, smoking, and alcohol consumption.
The principal sterol of all higher animals, distributed in body tissues, especially the brain and spinal cord, and in animal fats and oils.
A lipid-regulating agent that lowers elevated serum lipids primarily by decreasing serum triglycerides with a variable reduction in total cholesterol.
A generic term for fats and lipoids, the alcohol-ether-soluble constituents of protoplasm, which are insoluble in water. They comprise the fats, fatty oils, essential oils, waxes, phospholipids, glycolipids, sulfolipids, aminolipids, chromolipids (lipochromes), and fatty acids. (Grant & Hackh's Chemical Dictionary, 5th ed)
Concentrated pharmaceutical preparations of plants obtained by removing active constituents with a suitable solvent, which is evaporated away, and adjusting the residue to a prescribed standard.
Use of plants or herbs to treat diseases or to alleviate pain.
A plant genus of the family MALVACEAE. Members contain CITRIC ACID; MALATES; ANTHOCYANINS; FLAVONOIDS; GLYCOSIDES; DIETARY FIBER; and LIGNANS. Hibiscus sabdariffa is common constituent of HERBAL TEAS. Hibiscus cannabinus is a source of hemp fiber for TEXTILES.
A plant family of the order Violales, subclass Dilleniidae, class Magnoliopsida.
A plant genus of the family ASTERACEAE. Members contain INULIN, alantol, helenin, alantic acid, and acrid resin.
A plant family of the order Dilleniales, subclass Dilleniidae, class Magnoliopsida.
A plant genus in the LAURACEAE family. The bark of the trees is used in FOLK MEDICINE and FLAVORING AGENTS.
A class of nongenotoxic CARCINOGENS that induce the production of hepatic PEROXISOMES and induce hepatic neoplasms after long-term administration.
Substances used to lower plasma CHOLESTEROL levels.
An organization of cells into an organ-like structure. Organoids can be generated in culture. They are also found in certain neoplasms.
Cell wall components constituting a polysaccharide core found in fungi. They may act as antigens or structural substrates.
A genus of filamentous CYANOBACTERIA found in most lakes and ponds. It has been used as a nutritional supplement particularly due to its high protein content.
Physiological processes in biosynthesis (anabolism) and degradation (catabolism) of LIPIDS.
An ester of phthalic acid. It appears as a light-colored, odorless liquid and is used as a plasticizer for many resins and elastomers.
An enzyme that catalyzes the formation of O-acetylcarnitine from acetyl-CoA plus carnitine. EC 2.3.1.7.
A 9-kDa protein component of VERY-LOW-DENSITY LIPOPROTEINS and CHYLOMICRON REMNANTS. Apo C-III, synthesized in the liver, is an inhibitor of LIPOPROTEIN LIPASE. Apo C-III modulates the binding of chylomicron remnants and VLDL to receptors (RECEPTORS, LDL) thus decreases the uptake of triglyceride-rich particles by the liver cells and subsequent degradation. The normal Apo C-III is glycosylated. There are several polymorphic forms with varying amounts of SIALIC ACID (Apo C-III-0, Apo C-III-1, and Apo C-III-2).

Preventive effects of dehydroepiandrosterone acetate on the fatty liver induced by orotic acid in male rats. (1/1814)

Preventive effects of dehydroepiandrosteone acetate (DHEA-A) and clofibrate (positive control substance) on the fatty liver induced by orotic acid (OA) were examined on the male Sprague-Dawley rats fed a high sucrose based diet containing 1% OA and this diet further mixed with 0.5% DHEA-A or 0.5% clofibrate for 2 weeks. Numerous lipid droplets were observed in the hepatocytes of the rats treated with OA alone, but not in those treated with DHEA-A or clofibrate. In comparison to the group with OA alone, the DHEA-A or clofibrate treated rats showed a larger relative liver weight (to body weight) which was accompanied by increased peroxisomes in the hepatocytes. These results indicate that DHEA-A, as well as clofibrate, may prevent OA-induced fatty liver.  (+info)

Contribution of modern cardiovascular treatment and risk factor changes to the decline in coronary heart disease mortality in Scotland between 1975 and 1994. (2/1814)

OBJECTIVE: To estimate the fall in coronary heart disease (CHD) mortality in Scotland attributable to medical and surgical treatments, and risk factor changes, between 1975 and 1994. DESIGN: A cohort model combining effectiveness data from meta-analyses with information on treatment uptake in all patient categories in Scotland. SETTING AND PATIENTS: The whole Scottish population of 5.1 million, including all patients with recognised CHD. INTERVENTIONS: All cardiological, medical, and surgical treatments, and all risk factor changes between 1975 and 1994. Data were obtained from epidemiological surveys, routine National Health Service sources, and local audits. MAIN OUTCOME MEASURES: Deaths from CHD in 1975 and 1994. RESULTS: There were 15 234 deaths from CHD in 1994, 6205 fewer deaths than expected if there had been no decline from 1975 mortality rates. In 1994, the total number of deaths prevented or postponed by all treatments and risk factor reductions was estimated at 6747 (minimum 4790, maximum 10 695). Forty per cent of this benefit was attributed to treatments (initial treatments for acute myocardial infarction 10%, treatments for hypertension 9%, for secondary prevention 8%, for heart failure 8%, aspirin for angina 2%, coronary artery bypass grafting surgery 2%, and angioplasty 0.1%). Fifty one per cent of the reduction in deaths was attributed to measurable risk factor reductions (smoking 36%, cholesterol 6%, secular fall in blood pressure 6%, and changes in deprivation 3%). Other, unquantified factors apparently accounted for the remaining 9%. These proportions remained relatively consistent across a wide range of assumptions and estimates in a sensitivity analysis. CONCLUSIONS: Medical treatments and risk factor changes apparently prevented or postponed about 6750 coronary deaths in Scotland in 1994. Modest gains from individual treatments produced a large cumulative survival benefit. Reductions in major risk factors explained about half the fall in coronary mortality, emphasising the importance and future potential of prevention strategies.  (+info)

Cellular distribution of cytochromes P-450 in the rat kidney. (3/1814)

The distribution of several cytochrome P-450 (P-450) isoenzymes between proximal tubular (PT) and distal tubular (DT) cells of the rat kidney was determined. Western blot analysis of microsomes prepared from liver and kidney cortical homogenates revealed that CYP2E1 protein was expressed in rat kidney microsomes at approximately 10% of hepatic levels. Microsomes from renal cortical, PT, and DT cells all expressed CYP2E1, with DT microsomes expressing slightly higher levels than PT microsomes. In contrast, chlorzoxazone hydroxylation activity was markedly higher in microsomes from PT cells than in those from DT cells. Northern blot analysis of total RNA from PT and DT cells exhibited a pattern of CYP2E1 mRNA distribution similar to that of CYP2E1 protein. CYP2C11 protein expression in renal cortical microsomes was approximately 10% of that in liver microsomes but was significantly higher in microsomes from PT cells than in those from DT cells. CYP3A1/2 was not detected in microsomes from either cortical, PT, or DT cells, but was detected in microsomes isolated from total liver or kidney cortical homogenates. CYP2B1/2 expression was detected in all tissues tested. The peroxisomal proliferator clofibrate enhanced the level of CYP2B1/2 in microsomes from both total liver and kidney cortical homogenates but not in microsomes from cortical, PT, or DT cells. CYP4A2/3 protein and CYP4A mRNA expression were detected in microsomes from total liver and kidney cortical homogenates and from renal cortical, PT, and DT cells using Western and Northern blot analyses, respectively. Lauric acid hydroxylation activity, an indicator of CYP4A, was comparable in PT and DT cells. Clofibrate elevation of CYP4A in cortical, PT, and DT microsomes was not as great as that detected in total kidney cortical microsomes. These results establish the distribution of several P-450 isoenzymes between different cell populations of the rat kidney. Furthermore, these results present evidence that the level of induction of certain P-450 isoenzymes in the kidney is cell type-specific.  (+info)

Perfluorooctanoic acid, a peroxisome-proliferating hypolipidemic agent, dissociates apolipoprotein B48 from lipoprotein particles and decreases secretion of very low density lipoproteins by cultured rat hepatocytes. (4/1814)

The hypolipidemic effect is evoked by various peroxisome proliferators. Modulation of gene transcription via peroxisome proliferator-activated receptor (PPAR) is generally responsible for this effect. In addition, we have found a PPAR-independent mechanism in which fibrates, known peroxisome proliferators, decrease hepatic secretion of very low density lipoproteins (VLDL) through inhibition of phosphatidylcholine synthesis via methylation of phosphatidylethanolamine (PE) (T. Nishimaki-Mogami et al., Biochim. Biophys. Acta 1304 (1996) 21-31). In the present study, we show a novel mechanism by which perfluorooctanoic acid (PFOA), a potent peroxisome proliferator and inhibitor of PE methylation, exerts its hypolipidemic effect. PFOA (100 microM) added to the medium rapidly decreased the secretion of triglyceride by cultured rat hepatocytes, which was independent of the activity of cellular PE methylation. Analysis of the density of apoB secreted into the medium showed that PFOA decreased apoB48 in VLDL, but increased apoB48 in the bottom d>1.21 fraction. This lipid-poor apoB48 was also generated by incubating medium that had been harvested from control cells with PFOA, indicating that PFOA has the ability to dissociate apoB48 from lipoprotein particles. Exposure of cells to PFOA for 2 h prior to the experiment was sufficient to generate lipid-poor apoB48, indicating that PFOA exerted its effect intracellularly. Taken together, the data suggest that a strong interaction of PFOA with apoB48 disturbs the association of apoB48 with lipids in the process of intracellular VLDL assembly, thereby inhibiting VLDL secretion. This study shows that the mechanisms of hypolipidemic effect caused by various classes of peroxisome proliferators are diverse.  (+info)

Identifying and managing patients with hyperlipidemia. (5/1814)

Cardiovascular disease related to hyperlipidemia is a significant cause of morbidity and mortality in the United States. The benefit of lowering lipid levels in patients with and without cardiovascular disease has been demonstrated in numerous clinical trials. The results of these trials prompted the National Heart, Blood, and Lung Institute to form the Nation Cholesterol Education Panel (NCEP). This panel developed guidelines for identifying and treating lipid disorders. Before starting antilipemic therapy, patients should be evaluated for secondary causes of hyperlipidemia, including disease states and medications. Risk factors for cardiovascular disease should be identified and used to determine the patient's goal low-density lipoprotein level. Regardless of the drug therapy used, the cornerstone treatment for hyperlipidemia is dietary changes. The NCEP recommendation for dietary modification follows a two-step plan to reduce intake of cholesterol and dietary fats. Other nonpharmacologic treatments for hyperlipidemia include exercise, weight reduction for obese patients, reduction of excessive alcohol use, and smoking cessation . Drug therapy should be considered in patients who do not respond to an adequate trial of dietary modifications and lifestyle changes. The principal lipid-lowering agents currently used are the bile acid sequestrants, nicotinic acid, 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA) reductase inhibitors, and fibric acid derivatives. Estrogen, fish oil, and alcohol also can decrease the risk of developing heart disease. In pharmacoeconomic studies, lipid-lowering drug therapy has been shown to decrease the number of procedures, hospitalizations, and other medical interventions required by patients with cardiovascular disease.  (+info)

Phytanic acid is ligand and transcriptional activator of murine liver fatty acid binding protein. (6/1814)

Branched-chain phytanic acid is metabolized in liver peroxisomes. Sterol carrier protein 2/sterol carrier protein x (SCP2/SCPx) knockout mice, which develop a phenotype with a deficiency in phytanic acid degradation, accumulate dramatically high concentrations of this fatty acid in serum (Seedorf at al. 1998. Genes Dev. 12: 1189-1201) and liver. Concomitantly, a 6.9-fold induction of liver fatty acid binding protein (L-FABP) expression is observed in comparison to wild-type animals fed standard chow, possibly mediated by the peroxisome proliferator-activated receptor alpha (PPARalpha). Cytosolic transport of phytanic acid to either peroxisomal membranes or to the nucleus for activation of PPARalpha may be mediated by L-FABP, which gives rise to the question whether phytanic acid is a transactivator of this protein. Here we show first that phytanic acid binds to recombinant L-FABP with high affinity. Then the increase of the in vivo phytanic acid concentration by phytol feeding to mice results in a 4-fold induction of L-FABP expression in liver, which is in the order of that attained with bezafibrate, a known peroxisome proliferator. Finally to test in vitro whether this induction is conferred by phytanic acid, we cotransfected HepG2 cells with an expression plasmid for murine PPARalpha and a CAT-reporter gene with 176 bp of the murine L-FABP promoter, containing the peroxisome proliferator responsive element (PPRE). After incubation with phytanic acid, we observed a 3.2-fold induction of CAT expression. These findings, both in vivo and in vitro, demonstrate that phytanic acid is a transcriptional activator of L-FABP expression and that this effect is mediated via PPARalpha.  (+info)

Effect of gemfibrozil in vitro on fat-mobilizing lipolysis in human adipose tissue. (7/1814)

Fat-mobilizing lipolysis was studied in rat and human adipose tissue during incubation in vitro by following the release of glycerol into the incubation medium. Gemfibrozil as well as clofibrate consistently and readily inhibited basal as well as noradrenaline-stimulated fat-mobilizing lipolysis in rat fat. With human adipose tissue no effect was observed with gemfibrozil and clofibrate on basal lipolysis. This may be due to the comparatively low rate of the nonstimulated fat-mobilizing lipolysis in human tissue incubated in vitro. When lipolysis was stimulated with noradrenaline as well as isoprenaline, however, both gemfibrozil and clofibrate significantly reduced the fat-mobilizing lipolysis. This inhibition of lipolysis was however not observed in all studies. When lipolysis had been stimulated with theophylline, no inhibition of lipolysis was obtained with either compound. The possibility that reduced fat-mobilizing lipolysis in adipose tissue may cause a lowering of plasma triglycerides by reducing the flow of FFA to the liver is discussed in some detail. It is also suggested that inhibition of lipolysis may be accompanied by increased activity of lipoprotein lipase as well as an increase in the FIAT process. However, the pharmacological implication of the above-mentioned findings, particularly for gemfibrozil, must await further studies, as fairly large doses, around 1 mg/ml of incubation medium, were needed to obtain inhibition of fat-mobilizing lipolysis.  (+info)

Gemfibrozil in a group of diabetics. (8/1814)

A group of 14 diabetic patients was treated with gemfibrozil during a variable length of time ranging from nine to 23 weeks in order to establish if a lowering effect on the cholesterol and triglyceride levels could be achieved, as it had been in the case of another group of non-diabetic patients. The present results showed that: (1) The drug is remarkably well tolerated. (2) With doses ranging between 400 and 800 mg per day the magnitude of the effect of the drug was less than that observed in our previous trial with non-diabetic subjects. The effect upon triglycerides seemed to be reduced more than that upon cholesterol when compared with results in higher-dose studies. (3) In this group of diabetic patients (3 insulin dependent, 11 maturity-onset type) control of the diabetic condition was never impaired and appeared in some cases to be slightly improved by gemfibrozil. (4) There was no evidence of undesirable interaction with any of the anti-diabetic drugs used.  (+info)

Hypolipidemic agents are a class of medications that are used to lower the levels of lipids (fats) in the blood, particularly cholesterol and triglycerides. These drugs work by reducing the production or increasing the breakdown of fats in the body, which can help prevent or treat conditions such as hyperlipidemia (high levels of fats in the blood), atherosclerosis (hardening and narrowing of the arteries), and cardiovascular disease.

There are several different types of hypolipidemic agents, including:

1. Statins: These drugs block the action of an enzyme called HMG-CoA reductase, which is necessary for the production of cholesterol in the liver. By reducing the amount of cholesterol produced, statins can help lower LDL (bad) cholesterol levels and increase HDL (good) cholesterol levels.
2. Bile acid sequestrants: These drugs bind to bile acids in the intestines and prevent them from being reabsorbed into the bloodstream. This causes the liver to produce more bile acids, which requires it to use up more cholesterol, thereby lowering LDL cholesterol levels.
3. Nicotinic acid: Also known as niacin, this drug can help lower LDL and VLDL (very low-density lipoprotein) cholesterol levels and increase HDL cholesterol levels. It works by reducing the production of fatty acids in the liver.
4. Fibrates: These drugs are used to treat high triglyceride levels. They work by increasing the breakdown of fats in the body and reducing the production of VLDL cholesterol in the liver.
5. PCSK9 inhibitors: These drugs block the action of a protein called PCSK9, which helps regulate the amount of LDL cholesterol in the blood. By blocking PCSK9, these drugs can help lower LDL cholesterol levels.

It's important to note that hypolipidemic agents should only be used under the guidance and supervision of a healthcare provider, as they can have side effects and may interact with other medications.

Clofibrate is a medication that belongs to the class of drugs known as fibrates. It is primarily used to lower elevated levels of cholesterol and other fats (lipids) in the blood, specifically low-density lipoprotein (LDL), or "bad" cholesterol, and triglycerides, while increasing high-density lipoprotein (HDL), or "good" cholesterol. Clofibrate works by reducing the production of very-low-density lipoproteins (VLDL) in the liver, which in turn lowers triglyceride levels and indirectly reduces LDL cholesterol levels.

Clofibrate is available in oral tablet form and is typically prescribed for patients with high cholesterol or triglycerides who are at risk of cardiovascular disease, such as those with a history of heart attacks, strokes, or peripheral artery disease. It is important to note that clofibrate should be used in conjunction with lifestyle modifications, including a healthy diet, regular exercise, and smoking cessation.

Like all medications, clofibrate can have side effects, some of which may be serious. Common side effects include stomach upset, diarrhea, gas, and changes in taste. Less commonly, clofibrate can cause more severe side effects such as liver or muscle damage, gallstones, and an increased risk of developing certain types of cancer. Patients taking clofibrate should be monitored regularly by their healthcare provider to ensure that the medication is working effectively and to monitor for any potential side effects.

Microbodies are small, membrane-bound organelles found in the cells of eukaryotic organisms. They typically measure between 0.2 to 0.5 micrometers in diameter and play a crucial role in various metabolic processes, particularly in the detoxification of harmful substances and the synthesis of lipids.

There are several types of microbodies, including:

1. Peroxisomes: These are the most common type of microbody. They contain enzymes that help break down fatty acids and amino acids, producing hydrogen peroxide as a byproduct. Another set of enzymes within peroxisomes then converts the harmful hydrogen peroxide into water and oxygen, thus detoxifying the cell.
2. Glyoxysomes: These microbodies are primarily found in plants and some fungi. They contain enzymes involved in the glyoxylate cycle, a metabolic pathway that helps convert stored fats into carbohydrates during germination.
3. Microbody-like particles (MLPs): These are smaller organelles found in certain protists and algae. Their functions are not well understood but are believed to be involved in lipid metabolism.

It is important to note that microbodies do not have a uniform structure or function across all eukaryotic cells, and their specific roles can vary depending on the organism and cell type.

The liver is a large, solid organ located in the upper right portion of the abdomen, beneath the diaphragm and above the stomach. It plays a vital role in several bodily functions, including:

1. Metabolism: The liver helps to metabolize carbohydrates, fats, and proteins from the food we eat into energy and nutrients that our bodies can use.
2. Detoxification: The liver detoxifies harmful substances in the body by breaking them down into less toxic forms or excreting them through bile.
3. Synthesis: The liver synthesizes important proteins, such as albumin and clotting factors, that are necessary for proper bodily function.
4. Storage: The liver stores glucose, vitamins, and minerals that can be released when the body needs them.
5. Bile production: The liver produces bile, a digestive juice that helps to break down fats in the small intestine.
6. Immune function: The liver plays a role in the immune system by filtering out bacteria and other harmful substances from the blood.

Overall, the liver is an essential organ that plays a critical role in maintaining overall health and well-being.

Fenofibrate is a medication that belongs to the class of drugs known as fibrates. It is primarily used to lower levels of cholesterol and other fats (triglycerides) in the blood. Fenofibrate works by increasing the breakdown and elimination of these fats from the body, which can help reduce the risk of heart disease and stroke.

Fenofibrate is available in various forms, including tablets and capsules, and is typically taken once or twice a day with meals. Common side effects of fenofibrate include headache, nausea, and muscle pain. More serious side effects are rare but can include liver damage, kidney problems, and an increased risk of gallstones.

It's important to note that fenofibrate should be used in conjunction with a healthy diet, regular exercise, and other lifestyle changes to manage high cholesterol and triglyceride levels effectively. Additionally, patients taking fenofibrate should be monitored regularly by their healthcare provider to ensure that the medication is working properly and to check for any potential side effects.

Bezafibrate is a medication that belongs to a class of drugs called fibrates. It is primarily used to treat high cholesterol and related conditions, such as hyperlipidemia and mixed dyslipidemia. The medication works by reducing the levels of triglycerides and increasing the levels of "good" cholesterol (HDL) in the blood.

Bezafibrate achieves this effect by activating certain receptors in the body, known as peroxisome proliferator-activated receptors (PPARs), which play a role in regulating lipid metabolism. By binding to these receptors, bezafibrate helps to promote the breakdown of fats and reduce the production of cholesterol in the liver.

It is important to note that bezafibrate should be used in conjunction with lifestyle modifications, such as a healthy diet and regular exercise, to effectively manage high cholesterol and related conditions. Additionally, it may interact with other medications, so it is essential to inform your healthcare provider of all the drugs you are taking before starting bezafibrate therapy.

As with any medication, bezafibrate can cause side effects, including gastrointestinal symptoms such as nausea, diarrhea, and abdominal pain, as well as headaches, muscle cramps, and skin rashes. In rare cases, it may also cause more serious side effects, such as liver or kidney damage, so regular monitoring of liver and kidney function is recommended during treatment.

Overall, bezafibrate is a valuable tool in the management of high cholesterol and related conditions, but it should be used under the guidance and supervision of a healthcare professional to ensure safe and effective use.

Clofibric acid is the main metabolic product of clofibrate, a medication that belongs to the class of drugs called fibrates. It works by lowering levels of total and LDL (low-density lipoprotein) cholesterol and triglycerides in the blood, while increasing HDL (high-density lipoprotein) cholesterol levels. Clofibric acid is an antihyperlipidemic agent that is used primarily for the treatment of hypertriglyceridemia and mixed dyslipidemia. It may also be used to prevent pancreatitis caused by high triglyceride levels.

Clofibric acid is detectable in the urine and can be used as a biomarker for clofibrate exposure or use. However, it's important to note that clofibrate has largely been replaced by newer fibrates and statins due to its adverse effects profile and lower efficacy compared to these newer agents.

Hyperlipidemias are a group of disorders characterized by an excess of lipids (fats) or lipoproteins in the blood. These include elevated levels of cholesterol, triglycerides, or both. Hyperlipidemias can be inherited (primary) or caused by other medical conditions (secondary). They are a significant risk factor for developing cardiovascular diseases, such as atherosclerosis and coronary artery disease.

There are two main types of lipids that are commonly measured in the blood: low-density lipoprotein (LDL) cholesterol, often referred to as "bad" cholesterol, and high-density lipoprotein (HDL) cholesterol, known as "good" cholesterol. High levels of LDL cholesterol can lead to the formation of plaques in the arteries, which can narrow or block them and increase the risk of heart attack or stroke. On the other hand, high levels of HDL cholesterol are protective because they help remove LDL cholesterol from the bloodstream.

Triglycerides are another type of lipid that can be measured in the blood. Elevated triglyceride levels can also contribute to the development of cardiovascular disease, particularly when combined with high LDL cholesterol and low HDL cholesterol levels.

Hyperlipidemias are typically diagnosed through a blood test that measures the levels of various lipids and lipoproteins in the blood. Treatment may include lifestyle changes, such as following a healthy diet, getting regular exercise, losing weight, and quitting smoking, as well as medication to lower lipid levels if necessary.

Fibric acids, also known as fibric acid derivatives, are a class of medications that are primarily used to lower elevated levels of triglycerides (a type of fat) in the blood. They work by increasing the breakdown and removal of triglycerides from the bloodstream, and reducing the production of very-low-density lipoprotein (VLDL), a type of particle that carries triglycerides in the blood.

Examples of fibric acids include gemfibrozil, fenofibrate, and clofibrate. These medications are often prescribed for people with high triglyceride levels who are at risk for pancreatitis (inflammation of the pancreas) or other complications related to high triglycerides.

Fibric acids may also have a modest effect on raising levels of high-density lipoprotein (HDL), or "good" cholesterol, and lowering levels of low-density lipoprotein (LDL), or "bad" cholesterol, in some people. However, they are generally not as effective at lowering LDL cholesterol as statins, another class of cholesterol-lowering medications.

It's important to note that fibric acids can interact with other medications and may cause side effects such as stomach upset, muscle pain, and an increased risk of gallstones. As with any medication, it's important to use fibric acids under the guidance of a healthcare provider.

Nafenopin is not a medication that has been approved by the US Food and Drug Administration (FDA) for use in humans. Therefore, there is no established medical definition or indication for its use in human medicine.

However, Nafenopin is a drug that has been studied in animals as a potential treatment for brain injuries and neurological disorders. It is a type of medication called a non-selective opioid receptor antagonist, which means it blocks the effects of opioids (drugs that act on the body's natural pain-relieving system) in the brain.

In animal studies, Nafenopin has been shown to have neuroprotective effects and may help reduce damage to brain cells after an injury or stroke. However, more research is needed to determine its safety and effectiveness in humans before it can be approved for use as a medication.

Triglycerides are the most common type of fat in the body, and they're found in the food we eat. They're carried in the bloodstream to provide energy to the cells in our body. High levels of triglycerides in the blood can increase the risk of heart disease, especially in combination with other risk factors such as high LDL (bad) cholesterol, low HDL (good) cholesterol, and high blood pressure.

It's important to note that while triglycerides are a type of fat, they should not be confused with cholesterol, which is a waxy substance found in the cells of our body. Both triglycerides and cholesterol are important for maintaining good health, but high levels of either can increase the risk of heart disease.

Triglyceride levels are measured through a blood test called a lipid panel or lipid profile. A normal triglyceride level is less than 150 mg/dL. Borderline-high levels range from 150 to 199 mg/dL, high levels range from 200 to 499 mg/dL, and very high levels are 500 mg/dL or higher.

Elevated triglycerides can be caused by various factors such as obesity, physical inactivity, excessive alcohol consumption, smoking, and certain medical conditions like diabetes, hypothyroidism, and kidney disease. Medications such as beta-blockers, steroids, and diuretics can also raise triglyceride levels.

Lifestyle changes such as losing weight, exercising regularly, eating a healthy diet low in saturated and trans fats, avoiding excessive alcohol consumption, and quitting smoking can help lower triglyceride levels. In some cases, medication may be necessary to reduce triglycerides to recommended levels.

Cholesterol is a type of lipid (fat) molecule that is an essential component of cell membranes and is also used to make certain hormones and vitamins in the body. It is produced by the liver and is also obtained from animal-derived foods such as meat, dairy products, and eggs.

Cholesterol does not mix with blood, so it is transported through the bloodstream by lipoproteins, which are particles made up of both lipids and proteins. There are two main types of lipoproteins that carry cholesterol: low-density lipoproteins (LDL), also known as "bad" cholesterol, and high-density lipoproteins (HDL), also known as "good" cholesterol.

High levels of LDL cholesterol in the blood can lead to a buildup of cholesterol in the walls of the arteries, increasing the risk of heart disease and stroke. On the other hand, high levels of HDL cholesterol are associated with a lower risk of these conditions because HDL helps remove LDL cholesterol from the bloodstream and transport it back to the liver for disposal.

It is important to maintain healthy levels of cholesterol through a balanced diet, regular exercise, and sometimes medication if necessary. Regular screening is also recommended to monitor cholesterol levels and prevent health complications.

Gemfibrozil is a medication that belongs to a class of drugs called fibrates. It is primarily used to lower elevated levels of triglycerides (a type of fat found in the blood) and increase levels of "good" cholesterol (HDL-C) in the blood.

Gemfibrozil works by reducing the production of triglycerides in the body, increasing the breakdown of fats in the liver, and improving the way the body handles fats and sugar. It is often prescribed for people with high triglyceride levels who are at risk for pancreatitis (inflammation of the pancreas) or those who have not responded well to other cholesterol-lowering medications, such as statins.

It's important to note that while gemfibrozil can help manage triglyceride and cholesterol levels, it is not a substitute for a healthy lifestyle. Regular exercise, a balanced diet, limiting alcohol consumption, and avoiding smoking are all crucial components of maintaining good cardiovascular health.

As with any medication, gemfibrozil should be taken under the supervision of a healthcare provider, who can monitor its effectiveness and potential side effects. Common side effects of gemfibrozil include stomach pain, diarrhea, and muscle or joint pain. Rare but serious side effects may include liver damage, kidney problems, and an increased risk of gallstones.

Lipids are a broad group of organic compounds that are insoluble in water but soluble in nonpolar organic solvents. They include fats, waxes, sterols, fat-soluble vitamins (such as vitamins A, D, E, and K), monoglycerides, diglycerides, triglycerides, and phospholipids. Lipids serve many important functions in the body, including energy storage, acting as structural components of cell membranes, and serving as signaling molecules. High levels of certain lipids, particularly cholesterol and triglycerides, in the blood are associated with an increased risk of cardiovascular disease.

A plant extract is a preparation containing chemical constituents that have been extracted from a plant using a solvent. The resulting extract may contain a single compound or a mixture of several compounds, depending on the extraction process and the specific plant material used. These extracts are often used in various industries including pharmaceuticals, nutraceuticals, cosmetics, and food and beverage, due to their potential therapeutic or beneficial properties. The composition of plant extracts can vary widely, and it is important to ensure their quality, safety, and efficacy before use in any application.

Phytotherapy is the use of extracts of natural origin, especially plants or plant parts, for therapeutic purposes. It is also known as herbal medicine and is a traditional practice in many cultures. The active compounds in these plant extracts are believed to have various medicinal properties, such as anti-inflammatory, analgesic, or sedative effects. Practitioners of phytotherapy may use the whole plant, dried parts, or concentrated extracts to prepare teas, capsules, tinctures, or ointments for therapeutic use. It is important to note that the effectiveness and safety of phytotherapy are not always supported by scientific evidence, and it should be used with caution and preferably under the guidance of a healthcare professional.

I'm sorry for any confusion, but "Hibiscus" is not a medical term. It is a genus of flowering plants in the mallow family, Malvaceae. Some hibiscus species are used in traditional medicine and food products, but there isn't a single medical definition associated with the term "Hibiscus."

For example, Hibiscus sabdariffa, also known as roselle, is often used in herbal teas and has been studied for its potential health benefits. Some research suggests it may help lower blood pressure, but more studies are needed to confirm these findings and understand the mechanism of action.

If you're looking for information on a specific medical aspect related to hibiscus or its extracts, please provide more context so I can give you a more accurate response.

I apologize for any confusion, but "Violaceae" is not a medical term. It is the biological name of a family of flowering plants, also known as the violet family. This family includes various plants that may have medicinal uses, such as violets and pansies, but "Violaceae" itself does not have a specific medical definition.

"Inula" is a term that refers to a genus of flowering plants in the family Asteraceae. These plants are native to Europe, Asia, and Africa, and include several species such as I. helenium (Elecampane), I. racemosa (Horseheal), and I. viscosa (Sticky Inula). While some Inula species have been used in traditional medicine for their anti-inflammatory, expectorant, and diuretic properties, "Inula" itself is not a medical term or concept. It's essential to consult with a healthcare professional before using any plant or herbal remedy for medicinal purposes.

Dilleniaceae is a family of flowering plants that includes around 30 genera and 600 species. These plants are primarily found in tropical and subtropical regions, with a few species occurring in temperate zones. The family is characterized by having five or often many sepals and petals, numerous stamens, and a superior ovary.

The plants in Dilleniaceae are quite diverse, ranging from small herbs to large trees. Some of the more well-known members of this family include the Indian rubber tree (Dillenia indica), the cape gooseberry (Physalis peruviana), and the mock orange (Philadelphus coronarius).

It's worth noting that while Dilleniaceae is a distinct family of plants, it has been subject to significant reclassification in recent years. Some botanists have proposed merging it with other families or splitting it into smaller groups, so its exact composition and boundaries may continue to evolve as more research is conducted.

'Cinnamomum' is a genus name in the plant family Lauraceae, which includes several species of trees that are sources of cinnamon, a popular spice. The bark of these trees is dried and ground into a powder or rolled into quills, which are used to flavor food and drinks.

Two common species of Cinnamomum that are used for their aromatic bark are:

1. Cinnamomum verum (also known as Ceylon cinnamon or "true" cinnamon) - This species is native to Sri Lanka and southern India, and its bark has a sweet, delicate flavor and aroma. It contains less coumarin, a compound that can be harmful in large amounts, compared to other cinnamon species.
2. Cinnamomum cassia (also known as Chinese cinnamon or "cassia") - This species is native to southern China and Southeast Asia, and its bark has a stronger, more pungent flavor and aroma than Ceylon cinnamon. It contains higher levels of coumarin, which may pose health concerns if consumed in large quantities.

It's important to note that 'Cinnamomum' is a plant genus name and not a medical term or diagnosis. However, the spice derived from these trees, cinnamon, has been studied for its potential medicinal properties, including anti-inflammatory, antioxidant, and blood sugar regulation effects. More research is needed to confirm these benefits and determine safe and effective dosages.

Peroxisome proliferators are a class of synthetic compounds that can induce the proliferation (i.e., increase in number) of peroxisomes in the cells of various organisms, including mammals. These compounds include certain pharmaceuticals, industrial chemicals, and environmental pollutants.

Peroxisomes are small, membrane-bound organelles found in the cytoplasm of eukaryotic cells (cells with a true nucleus). They play a crucial role in several metabolic processes, including the breakdown of fatty acids, the detoxification of harmful substances, and the biosynthesis of certain lipids.

Peroxisome proliferators exert their effects by binding to and activating specific nuclear receptors called peroxisome proliferator-activated receptors (PPARs). PPARs are transcription factors that regulate the expression of genes involved in cellular metabolism, differentiation, and growth. Activation of PPARs by peroxisome proliferators leads to an increase in peroxisome number and altered peroxisomal functions, which can have various consequences for cellular homeostasis and overall organism health.

It is important to note that long-term exposure to certain peroxisome proliferators has been linked to increased risks of cancer and other diseases in animals, although the evidence in humans is less clear. Further research is needed to fully understand the potential health impacts of these compounds.

Anticholesteremic agents are a class of medications that are used to lower the levels of cholesterol and other fats called lipids in the blood. These medications work by reducing the production of cholesterol in the body, increasing the removal of cholesterol from the bloodstream, or preventing the absorption of cholesterol in the digestive tract.

There are several types of anticholesteremic agents, including:

1. Statins: These medications work by blocking a liver enzyme that is necessary for the production of cholesterol. Examples of statins include atorvastatin, simvastatin, and rosuvastatin.
2. Bile acid sequestrants: These medications bind to bile acids in the digestive tract and prevent them from being reabsorbed into the bloodstream. This causes the liver to produce more bile acids, which in turn lowers cholesterol levels. Examples of bile acid sequestrants include cholestyramine and colesevelam.
3. Nicotinic acid: Also known as niacin, this medication works by reducing the production of very low-density lipoproteins (VLDL) in the liver, which are a major source of bad cholesterol.
4. Fibrates: These medications work by increasing the removal of cholesterol from the bloodstream and reducing the production of VLDL in the liver. Examples of fibrates include gemfibrozil and fenofibrate.
5. PCSK9 inhibitors: These are a newer class of medications that work by blocking the action of a protein called PCSK9, which helps regulate the amount of cholesterol in the blood. By blocking PCSK9, these medications increase the number of LDL receptors on the surface of liver cells, which leads to increased removal of LDL from the bloodstream.

Anticholesteremic agents are often prescribed for people who have high cholesterol levels and are at risk for heart disease or stroke. By lowering cholesterol levels, these medications can help reduce the risk of heart attack, stroke, and other cardiovascular events.

Organoids are 3D tissue cultures grown from stem cells that mimic the structure and function of specific organs. They are used in research to study development, disease, and potential treatments. The term "organoid" refers to the fact that these cultures can organize themselves into structures that resemble rudimentary organs, with differentiated cell types arranged in a pattern similar to their counterparts in the body. Organoids can be derived from various sources, including embryonic stem cells, induced pluripotent stem cells (iPSCs), or adult stem cells, and they provide a valuable tool for studying complex biological processes in a controlled laboratory setting.

Fungal polysaccharides refer to complex carbohydrates that are produced and found in fungi, including yeasts, molds, and mushrooms. These polysaccharides are made up of long chains of sugar molecules that are linked together by glycosidic bonds.

Fungal polysaccharides have various structures and functions depending on the specific fungal species they come from. Some fungal polysaccharides, such as beta-glucans, have been shown to have immunomodulatory effects and are used in some medical treatments. Beta-glucans, for example, can stimulate the immune system's response to infections and cancer.

Other fungal polysaccharides, such as chitin, are structural components of fungal cell walls. Chitin is a polysaccharide made up of N-acetylglucosamine units and is also found in the exoskeletons of insects and crustaceans.

Fungal polysaccharides have been studied for their potential therapeutic uses, including as antimicrobial, antitumor, and immunomodulatory agents. However, more research is needed to fully understand their mechanisms of action and potential benefits and risks.

Spirulina is not typically considered in medical definitions, as it is a type of blue-green algae that is often used as a dietary supplement or superfood due to its high nutritional content. However, here's a brief description:

Spirulina (Arthrospira spp.) is a filamentous, spiral-shaped, photosynthetic cyanobacterium that grows in warm, alkaline fresh and brackish waters. It is often found in tropical and subtropical lakes with high pH values and high concentrations of carbonate and bicarbonate. Spirulina contains various nutrients such as proteins, carbohydrates, lipids, vitamins (including B12), minerals, carotenoids, and antioxidants like phycocyanobilin. It has been used for its potential health benefits, including boosting the immune system, reducing inflammation, supporting cardiovascular health, and providing antioxidant protection. However, it is essential to consult healthcare professionals before starting any dietary supplement regimen, as individual needs and responses may vary.

Lipid metabolism is the process by which the body breaks down and utilizes lipids (fats) for various functions, such as energy production, cell membrane formation, and hormone synthesis. This complex process involves several enzymes and pathways that regulate the digestion, absorption, transport, storage, and consumption of fats in the body.

The main types of lipids involved in metabolism include triglycerides, cholesterol, phospholipids, and fatty acids. The breakdown of these lipids begins in the digestive system, where enzymes called lipases break down dietary fats into smaller molecules called fatty acids and glycerol. These molecules are then absorbed into the bloodstream and transported to the liver, which is the main site of lipid metabolism.

In the liver, fatty acids may be further broken down for energy production or used to synthesize new lipids. Excess fatty acids may be stored as triglycerides in specialized cells called adipocytes (fat cells) for later use. Cholesterol is also metabolized in the liver, where it may be used to synthesize bile acids, steroid hormones, and other important molecules.

Disorders of lipid metabolism can lead to a range of health problems, including obesity, diabetes, cardiovascular disease, and non-alcoholic fatty liver disease (NAFLD). These conditions may be caused by genetic factors, lifestyle habits, or a combination of both. Proper diagnosis and management of lipid metabolism disorders typically involves a combination of dietary changes, exercise, and medication.

Diethylhexyl Phthalate (DEHP) is a type of phthalate compound that is commonly used as a plasticizer, a substance added to plastics to make them more flexible and durable. DEHP is a colorless, oily liquid with an odor similar to oil or benzene. It is soluble in organic solvents but not in water.

DEHP is used primarily in the production of polyvinyl chloride (PVC) plastics, such as flexible tubing, hoses, and medical devices like blood bags and intravenous (IV) lines. DEHP can leach out of these products over time, particularly when they are subjected to heat or other stressors, leading to potential human exposure.

Exposure to DEHP has been linked to a variety of health effects, including reproductive toxicity, developmental and neurological problems, and an increased risk of cancer. As a result, the use of DEHP in certain applications has been restricted or banned in some countries. The medical community is also moving towards using alternative plasticizers that are considered safer for human health.

Carnitine O-acetyltransferase (COAT) is an enzyme that plays a crucial role in the transport and metabolism of fatty acids within cells. It is also known as carnitine palmitoyltransferase I (CPT I).

The primary function of COAT is to catalyze the transfer of an acetyl group from acetyl-CoA to carnitine, forming acetylcarnitine and free CoA. This reaction is essential for the entry of long-chain fatty acids into the mitochondrial matrix, where they undergo beta-oxidation to produce energy in the form of ATP.

COAT is located on the outer membrane of the mitochondria and functions as a rate-limiting enzyme in fatty acid oxidation. Its activity can be inhibited by malonyl-CoA, which is an intermediate in fatty acid synthesis. This inhibition helps regulate the balance between fatty acid oxidation and synthesis, ensuring that cells have enough energy while preventing excessive accumulation of lipids.

Deficiencies or mutations in COAT can lead to various metabolic disorders, such as carnitine palmitoyltransferase I deficiency (CPT I deficiency), which may cause symptoms like muscle weakness, hypoglycemia, and cardiomyopathy. Proper diagnosis and management of these conditions often involve dietary modifications, supplementation with carnitine, and avoidance of fasting to prevent metabolic crises.

Apolipoprotein C-III (APOC3) is a protein that is produced in the liver and circulates in the bloodstream. It is a component of certain lipoproteins, including very low-density lipoproteins (VLDL) and chylomicrons, which are responsible for transporting fat molecules, such as triglycerides and cholesterol, throughout the body.

APOC3 plays a role in regulating the metabolism of these lipoproteins. Specifically, it inhibits the activity of an enzyme called lipoprotein lipase, which breaks down triglycerides in VLDL and chylomicrons. As a result, high levels of APOC3 can lead to an increase in triglyceride levels in the blood, which is a risk factor for cardiovascular disease.

Genetic variations in the APOC3 gene have been associated with differences in triglyceride levels and risk of cardiovascular disease. Some studies have suggested that reducing APOC3 levels through genetic editing or other means may be a promising strategy for lowering triglycerides and reducing the risk of heart disease.

Bencze WL, Hess R, DeStevens G (6 December 2012). "Hypolipidemic agents". Progress in Drug Research. Fortschritte der ... It is metabolized into isoniazid, an anti-tuberculosis agent, and so is contraindicated in patients with tuberculosis. The ...
... is a sulfamylbenzoic acid that acts as a hypolipidemic agent. Although it was found to be more powerful than ... "Hypolipidemic Agents". Progress in Drug Research / Fortschritte der Arzneimittelforschung / Progrès des recherches ... Hypolipidemic agents, Sulfonamides, Abandoned drugs, Benzoic acids). ...
Antibodies, Hypolipidemic agents). ...
... is a hypolipidemic agent. Potì R, Quintavalla R, Manotti C (1977). "[Clinical experimentation with a new drug lowering ... Hypolipidemic agents, All stub articles, Cardiovascular system drug stubs). ...
... is a hypolipidemic agent. Levine, W.G.; Meijer, D.K.F. (1977), "THE CHOLERETIC EFFECT OF NAFENOPIN", Abstracts, ...
... is a fibrate, a hypolipidemic agent. It is a combined ester of clofibric acid and niacin (nicotinic acid) with 1,3- ...
Pharmacological therapies include hypolipidemic agents, thrombolytics and anticoagulants. Pharmacological options for reducing ... "Regulation of ET-1 biosynthesis in cerebral microvascular endothelial cells by vasoactive agents and PKC". American Journal of ... "Subarachnoid Hematoma Attenuates Vasodilation and Potentiates Vasoconstriction Induced by Vasoactive Agents in Newborn Pigs". ... "Subarachnoid Hematoma Attenuates Vasodilation and Potentiates Vasoconstriction Induced by Vasoactive Agents in Newborn Pigs". ...
... is a niacin derivative used as a hypolipidemic agent. It is an ester of pentaerythritol and nicotinic acid, has ...
... is a niacin derivative used as a hypolipidemic agent. Kopelevich VM, Gunar VI (1999). "Some approaches to the ...
Roth BD (2002). The discovery and development of atorvastatin, a potent novel hypolipidemic agent. Progress in Medicinal ... "Recommendations for Management of Clinically Significant Drug-Drug Interactions With Statins and Select Agents Used in Patients ... an effective lipid-modifying agent in familial hypercholesterolemia". Arteriosclerosis, Thrombosis, and Vascular Biology. 17 (8 ...
1. Hypolipidemic and hypoglycemic agents with ability to inhibit lipid peroxidation". Journal of Medicinal Chemistry. 32 (2): ...
... a Potent Novel Hypolipidemic Agent". Progress in Medicinal Chemistry. 40: 1-22. doi:10.1016/S0079-6468(08)70080-8. ISBN 978-0- ... a Potent Novel Hypolipidemic Agent". Prog. Med. Chem. Progress in Medicinal Chemistry. 40: 1-22. doi:10.1016/S0079-6468(08) ...
... is a niacin derivative used as a hypolipidemic agent. Budavari S, O'Neil M, Smith A, Heckelman P, ...
... (trade name Sedalipid) is a hypolipidemic agent. Schuitemaker GE, van der Pol GA, ... Hypolipidemic agents, All stub articles, Cardiovascular system drug stubs). ...
All articles with unsourced statements, Articles with unsourced statements from December 2015, Hypolipidemic agents). ...
... (compactin, ML-236B) is a hypolipidemic agent that belongs to the statins class. It was isolated from the mold ...
... is a derivative of acefylline and clofibrate used as a hypolipidemic agent. FR 2393803, Tamietto, Teresio ...
... a new hypolipidemic agent, on biliary and serum lipids in patients with hyperlipidemia". Atherosclerosis. 42 (2-3): 129-39. doi ...
... (pyridylcarbinol) is a niacin derivative used as a hypolipidemic agent and as a vasodilator. It causes ... At least a couple of uses for this agent were discovered over the years: Eniclobrate Mepiroxol Nicofibrate Pantenicate ( ...
In the body it is converted into 4-chlorophenoxyisobutyric acid (clofibric acid), which is the true hypolipidemic agent. So ...
... and are therefore hypolipidemic agents. Fibrates improve atherogenic dyslipidemia characterized by high triglyceride and/or low ... Clinical trials do support their use as monotherapy agents. Fibrates reduce the number of non-fatal heart attacks, but do not ...
Lipid-lowering agents, also sometimes referred to as hypolipidemic agents, cholesterol-lowering drugs, or antihyperlipidemic ... Flaxseed oil Investigational classes of hypolipidemic agents: CETP inhibitors (cholesteryl ester transfer protein), 1 candidate ... lipid lowering agent' be used for this class of drugs rather than the term 'hypolipidemic'. The several classes of lipid ... the choice of an agent depends on the patient's cholesterol profile, cardiovascular risk, and the liver and kidney functions of ...
Use of these agents as hypolipidemic agents has decreased markedly since the introduction of the statins, which are more ... In general, they are classified as hypolipidemic agents, although they may be used for purposes other than lowering cholesterol ...
Hypolipidemic agents, Benzoate esters, Substituted amphetamines, Trifluoromethyl compounds, Monoamine releasing agents, ... Benfluorex, sold under the brand name Mediator, is an anorectic and hypolipidemic agent that is structurally related to ...
... is a hypolipidemic agent. It occurs free in Crotalaria dura and C. globifera and is bound in dicrotaline (pyrrolizidine ... Hypolipidemic agents, Aldols, All stub articles, Cardiovascular system drug stubs). ...
In trophoblast-derived cell lines, up-regulated VLDLR expression occurs when cells are incubated with hypolipidemic agents such ...
Hypolipidemic agents, Discontinued products). ...
1994). Novel nematocidal agents from Curcuma comosa. J Nat Prod 57(2): 250-262. Suksamrarn, A., et al. (1997) A ... 1997). Hypolipidemic effect of Curcuma comosa in mice. Artery 22(5): 233-241. Piyachaturawat, P., J. Charoenpiboonsin, C. ...
... mainly as hypolipidemic agents, although they may be used for purposes other than lowering cholesterol. Solvent impregnated ...
Hypolipidemic agents, 3-Pyridyl compounds, Multiple Chemboxes). ... Costet P (June 2010). "Molecular pathways and agents for ... How effective are the different agents?". European Heart Journal Supplements. 8 (F): F47-F53. doi:10.1093/eurheartj/sul041. ... "Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid". Cell Metabolism. 12 (4): 411 ...
Hypolipidemic agents, or antihyperlipidemic agents, are a diverse group of pharmaceuticals that are used in the treatment of ... Hypolipidemic agent. Revision as of 16:12, 9 August 2012 by WikiBot. (talk , contribs) (Robot: Automated text replacement (-{{ ... They are called lipid-lowering drugs (LLD) or agents. Classes of hypolipidemic drugs. There are several classes of ... Investigational classes of hypolipidemic agents: *CETP Inhibitors (cholesteryl ester transfer protein inhibitors) are still ...
Bencze WL, Hess R, DeStevens G (6 December 2012). "Hypolipidemic agents". Progress in Drug Research. Fortschritte der ... It is metabolized into isoniazid, an anti-tuberculosis agent, and so is contraindicated in patients with tuberculosis. The ...
Hypolipidemic Agents / pharmacology * Hypolipidemic Agents / therapeutic use* * Intestinal Mucosa / metabolism* * Intestines / ...
ClinicalTrials.gov: Hypolipidemic Agents (National Institutes of Health) * ClinicalTrials.gov: Nicotinic Acids (National ...
Hypolipidemic Agents / pharmacology* * Hypolipidemic Agents / therapeutic use * PPAR alpha / antagonists & inhibitors * ...
Pharmacological Actions : Anti-Inflammatory Agents, Hypolipidemic, Tumor Necrosis Factor (TNF) Alpha Inhibitor ... Pharmacological Actions : Anti-Inflammatory Agents, Anticholesteremic Agents, Tumor Necrosis Factor (TNF) Alpha Inhibitor ... Pharmacological Actions : Anti-Inflammatory Agents, Anticarcinogenic Agents, Gastroprotective, Interleukin-1 beta ... Synbiotics may be a potential functional food or chemopreventive agent for controlling colorectal cancer.Dec 31, 2018. ...
Gastrointestinal Agents. 10. 25. Hypolipidemic. 4. 16. Neuroprotective Agents. 4. 15. Hypoglycemic Agents. 3. 13. ... Pharmacological Actions : Anti-Inflammatory Agents, Antihypertensive Agents, Gastrointestinal Agents, Interferon Gamma Reducer ... Pharmacological Actions : Anti-Inflammatory Agents, Antihypertensive Agents, Gastrointestinal Agents, Interleukin-6 ... Pharmacological Actions : Anti-Inflammatory Agents, Gastrointestinal Agents, Hepatoprotective, Interleukin-6 Downregulation. ...
It examines proteins and peptides as allergens, antihypertensive agents, antimicrobials, antioxidants, and anticancer agents. ... Hypolipidemic and Hypocholesterolemic Food Proteins and Peptides. Chibuike C. Udenigwe and Rotimi E. Aluko Peptides and ... Proteins and Peptides as Anticancer Agents. Harekrushna Panda, Aruna S. Jaiswal, and Satya Narayan Lunasin: A Novel Seed ... Food Proteins and Peptides as Bioactive Agents. Arvind Kannan, Navam Hettiarachchy, and Maurice Marshall Proteins and Peptides ...
Simvastatin is a commonly used cholesterol lowering agent (statin) that is associated with mild, asymptomatic and self-limited ... Review and discussion of individual lipid lowering agents; rate of ALT elevations during simvastatin therapy similar to that ... Hepatotoxicity of hypolipidemic drugs. Clin Liver Dis. 2003;7:415-33. [PubMed: 12879992]. ( ... and dose adjustments are appropriate for its use with other agents that inhibit CYP 3A4. Coadministration with these agents may ...
Cardiovascular Agents); 0 (Hypoglycemic Agents); 0 (Hypolipidemic Agents); ppublish ... Hypoglycemic Agents/therapeutic use, Hypolipidemic Agents/therapeutic use, Logistic Models, Male, Middle Aged, Myocardial ... Adult, Aged, Angioplasty, Balloon, Coronary, Antihypertensive Agents/therapeutic use, Cardiovascular Agents/therapeutic use, ... LR: 20101118; CI: Copyright 2010; ClinicalTrials.gov/NCT00387231; JID: 7903272; 0 (Antihypertensive Agents); 0 ( ...
Response of hepatic microbodies to a hypolipidemic agent, ethyl chlorophenoxyisobutyrate (CPIB). J Cell Biol. 1966;30:442-450. ... Fibric acid derivatives, which are available for use in humans as lipid lowering agents, serve as PPARα activators[4647]. In a ... although further human studies are needed to define the therapeutic role of these agents. ...
Clinical trial of gugulipid-a new hypolipidemic agent of plant origin in primary hyperlipidemia. Indian J Med Res 1986;84:626- ... Another homocysteine lowering agent, folic acid is essential for the formation of red and white blood cells and involved in the ... This has been known to medical science for many years.10 studies on niacin as a cholesterol-lowering agent go back to the ... Hypolipidemic effects of absorption of citrus polymethoxylated flavones in hamsters with diet-included hypercholesterolemia. J ...
... and Europe and has been used as a folk diuretic and hypolipidemic agent. Modern research in pharmacology and therapeutics found ... exhibit hypolipidemic, hypoglycaemic, and diuretic effects [2, 6, 7]. Alisol C 23-acetate promotes glucose uptake [2] and ... Anti-Cancer Agents in Medicinal Chemistry, vol. 15, no. 2, pp. 228-235, 2015. ... that RA possesses hypolipidemic, anti-inflammatory, hypoglycaemic, antihypertensive, antitumor, diuretic, and antifatty liver ...
Journal: Anti-Cancer Agents in Medicinal Chemistry. Volume: 19 Issue: 1 Year: 2019 Page: 1481-1490. Author(s): Doaa T. Ramadan, ... Hypolipidemic and Antioxidant Activities of Corrigiola telephiifolia in Diabetic Rats Journal: Cardiovascular & Hematological ... Agents in Medicinal Chemistry Volume: 17 Issue: 1 Year: 2019 Page: 47-51. Author(s): Morad Hebi,Mohamed Eddouks ...
Prasanna M. Hypolipidemic effect of fenugreek: a clinical study. Ind J Pharmacol. 2000;32:34-36.. * Cited Here ... and oils are approved as generally recognized as safe for typical use as a seasoning or flavoring agent by the US Food and Drug ... Hypolipidemic and antioxidant effects of fenugreek seeds and triphala as adjuncts to dietary therapy in patients with mild to ... HUMAN STUDIES OF HYPOGLYCEMIC AND HYPOLIPIDEMIC EFFECTS OF FENUGREEK. Since the 1980s, dozens of human studies, many from India ...
Insights into the antagonism of the hypolipidemic agent Z-guggulsterone. Biochim Biophys Acta 1844, 1684-1693, 10.1016/j.bbapap ... The hypolipidemic natural product guggulsterone is a promiscuous steroid receptor ligand. Mol Pharmacol 67, 948-954, 10.1124/ ... Hotson, I. K. The avermectins: A new family of antiparasitic agents. J S Afr Vet Assoc 53, 87-90 (1982). ... The recently discovered FXR agonist ivermectin10 and the other five avermectin macrolide antiparasitic agents (k3.3) identified ...
Twenty years later, milk thistle was acknowledged as a therapeutic agent against all types of toxic exposure. Ever since, this ... with both hypoglycemic and hypolipidemic effects." ... the potential of cinnamaldehyde for use as a natural oral agent ... Cinnamaldehyde-A potential antidiabetic agent Phytomedicine Volume 14, Issue 1, 10 January 2007, Pages 15-22 ...
Hypolipidemic effects of alisat and lipostabil in patients with diabetes mellitus. Ter Arkh. 2000;72(8):57-58. ... The most well-known of these early agents was Lipostabil Endovena® (Aventis Pharma, Germany), an intravenous agent for the ... Injectable agents based on mesotherapeutic preparations represent a new category of drugs targeting unwanted adipose tissue. ... FDA-approved trials of combined PC/SDC solutions and beta-adrenergic agents for injection lipolysis may lead to safer and more ...
... being treated with hypolipidemic agents. The control group comprised healthy volunteers with no stroke or history of stroke, or ...
... hypolipidemic, and weight-loss agents, as well as for diabetes and the metabolic syndrome.[6,11,12] The main constituent of ... It is also used medicinally as an anti-inflammatory, a laxative, or a hypoglycemic agent for diabetes and to treat gastritis. ... Like nopal, Gymnema may interact with oral hypoglycemic agents and increase the risk for hypoglycemia. Therefore, Gymnema ... Side effects include hypoglycemia (especially when used with hypoglycemic agents), diarrhea, dyspepsia, and flatulence at high ...
Although these classical hypolipidemic agents are generally well tolerated, most of them have adverse effects [49]; they only ... D. Rozman and K. Monostory, "Perspectives of the non-statin hypolipidemic agents," Pharmacology and Therapeutics, vol. 127, no ... The hypolipidemic effects of TCMs have been extensively investigated and manifested in vitro and in vivo and clinically ... A Review on the Traditional Chinese Medicinal Herbs and Formulae with Hypolipidemic Effect. Tung-Ting Sham. ,1Chi-On Chan. ,1,2 ...
In addition, an important role remains for other hypolipidemic agents that may be of particular benefit for patients with ... Drug Agents. HMG-CoA reductase inhibitors. These agents are competitive inhibitors of 3-hydroxy-3-methyl Co-A reductase, an ... Both classes of agents have benefits in reducing blood pressure and weight, and they have a low risk for hypoglycemia. ... These agents increase the activity of lipoprotein lipase and enhance the catabolism of triglyceride-rich lipoproteins, which is ...
Hypolipidemic effects of alkaloids from rhizoma coptidis in diet-induced hyperlipidemic hamsters. Planta Med. 2016;82(08):690-7 ... Rhizoma coptidis: a potential cardiovascular protective agent. Front Pharmacol. 2016;7:362. ...
Thus, results of the experimental study reveal that the leaf of Nelumbo nucifera has potent hypoglycemic and hypolipidemic ... The study was carried out to evaluate the hypolipidemic and hypoglycemic effect of Nelumbo nucifera leaf powder. In rats, ... forward for a sophisticated oral drug that will be therapeutically effective as hypoglycemic side by side hypolipidemic agents ... For the hypolipidemic activity evaluation, rats are divided into a total of eight groups consisting of six in each keeping the ...
Hypolipidemic Agents. *Hydroxymethylglutaryl-CoA Reductase Inhibitors. *Humans. *Cardiovascular System & Hematology. * ...
It is also used as a revitalizing agent. It is able to restore the beta cells of the pancreas to their normal working levels ... it has a hypolipidemic property due to which it is able to regulate the cholesterol levels. ... Gymnema Sylvestre also counters the effects of diabetes by acting as an anti-obesity agent. The experts believe that diabetes ... It protects the pancreatic cells from various inflammatory agents.. Bitter gourd has many essential nutrients beneficial for ...
The latter compounds, the SCAP ligands, are the first members of a new class of hypolipidemic agents affecting the ... New Lipid-Lowering Agents Acting on LDL Receptors Page: 642-660 (19). Author: Hubert Scharnagl, Tatjana Stojakovic and Winfried ... New Anticonvulsant Agents Page: 805-841 (37). Author: Barbara Malawska. DOI: 10.2174/978160805207310904010805. PDF Price: $15 ... Recent Advances in New Structural Classes of Anti-Tuberculosis Agents Page: 506-540 (35). Author: Amit Nayyar, Sanjay R. Patel ...
This protein is induced by treatment with hypolipidemic agents in parallel with peroxisome proliferation and stimulation of the ...
... and possibly with certain other hypolipidemic agents. In the Sprague-Dawley rat, very high, pharmacologically comparable ...
Similar results were also shown in lipid metabolism studies, in which hypolipidemic agents, namely fibrates, were used as PPARα ... 2016) Curcumin: a multi-target disease-modifying agent for late-stage transthyretin amyloidosis Scientific Reports 6:26623. ... The development of derivative agents based on curcumin with high bioavailability or specific effects may have far-reaching ...
  • The activation of PPARα leads to a cascade of events that result in the pharmacological (hypolipidemic) and adverse (carcinogenic) effects in rodent liver. (biomedcentral.com)
  • The study was carried out to evaluate the hypolipidemic and hypoglycemic effect of Nelumbo nucifera leaf powder. (scirp.org)
  • Thus, results of the experimental study reveal that the leaf of Nelumbo nucifera has potent hypoglycemic and hypolipidemic properties. (scirp.org)
  • Therefore, it is now inevitable to move forward for a sophisticated oral drug that will be therapeutically effective as hypoglycemic side by side hypolipidemic agents at low cost particularly both for the developing and under-developed countries. (scirp.org)
  • In rodents, the amine carboxyboranes were potent hypolipidemic agents, lowering both serum cholesterol and triglyceride concentrations, in addition to lowering cholesterol content of very low-density lipoprotein and low-density lipoprotein (LDL) and elevating high-density lipoprotein (HDL) cholesterol concentrations. (nih.gov)
  • Subsequent studies showed that the amine-carboxyboranes were potent anti-osteoporotic agents reducing calcium resorption as well as increasing calcium and proline incorporation into mouse pup calvaria and rat UMR-106 collagen. (nih.gov)
  • Development of a novel, fully human, anti-PCSK9 antibody with potent hypolipidemic activity by utilizing phage display-based strategy. (bvsalud.org)
  • Ripasudil free base is a selective and potent ROCK inhibitor, is a novel and potent antiglaucoma agent. (targetmol.com)
  • Tissue lipids in the aorta wall of the rat were reduced and fewer atherosclerotic morphologic lesions were present in quail aortas after treatment with the agents. (nih.gov)
  • The agents would effectively lower lipids in tissue based on the inhibition of regulatory enzymes in pigs. (nih.gov)
  • Concurrently, the agents modulated LDL and HDL receptor binding, internalization, and degradation, so that less cholesterol was delivered to the plaques and more broken down from esters and conducted to the liver for biliary excretion. (nih.gov)
  • Gemfibrozil (GEM) is a hypolipidemic agent, which is effective in reducing serum cholesterol and triglyceride levels. (unav.edu)
  • An antilipemic agent that lowers CHOLESTEROL and TRIGLYCERIDES . (bvsalud.org)
  • Fibrates are a unique hypolipidemic drugs that lower plasma triglyceride and cholesterol levels through their action as peroxisome proliferator-activated receptor alpha (PPARα) agonists. (biomedcentral.com)
  • When concomitant administration of cyclosporine, fibrates, erythromycin, clarithromycin, immunosuppressive, antifungal agents (belonging to azoles) and nicotinamide concentration of atorvastatin in plasma (and the risk of myopathy) increases. (pharmru.com)
  • Vytorin refers to the hypolipidemic drugs from the statines' class. (7daypharmacy.net)
  • Simvastatine is a hypolipidemic agent from a group of statins, an inhibitor of HMG-CoA reductase. (sdrugs.com)
  • In addition to the hypolipidemic actions Simvastatine has beneficial effects in endothelial dysfunction, on the vascular wall, the state of atheroma, improves blood rheology, have antioxidant, antiproliferative properties. (sdrugs.com)
  • Zetia covers to the hypolipidemic or lipid lowering medical preparations. (7daypharmacy.net)
  • Although the incidence of drug-induced skeletal muscle toxicity is very low (0.1-0.2%) with monotherapy, it may increase following concomitant drug therapy with the immunosuppressant, cyclosporine A (CsA), and possibly with certain other hypolipidemic agents. (aspetjournals.org)
  • Osorio-Esquivel, O., Cortés-Viguri, V., Garduño-Siciliano, L., Ortiz-Moreno, A. and Sánchez-Pardo, M.E. (2014) Hypolipidemic Activity of Microwave-Dehydrated Mango ( Mangifera indica L.) Powder in Mice Fed a Hyper- cholesterolemic Diet. (fdocument.org)
  • How to cite this paper: Osorio-Esquivel, O., Cortés-Viguri, V., Garduño-Siciliano, L., Ortiz-Moreno, A. and Sánchez-Pardo, M.E. (2014) Hypolipidemic Activity of Microwave-Dehydrated Mango (Mangifera indica L.) Powder in Mice Fed a Hyper-cholesterolemic Diet. (fdocument.org)
  • The amine-carboxyborane derivatives were shown to be effective antineoplastic/cytotoxic agents with selective activity against single-cell and solid tumors derived from murine and human leukemias, lymphomas, sarcomas, and carcinomas. (nih.gov)
  • For the hypolipidemic activity investigation, the selected animals are normally fed high fat diet to originate hyperlipidemia inside those animals. (scirp.org)
  • More significantly, the agents were dual inhibitors of prostaglandin cyclooxygenase and 5'-lipoxygenase activities. (nih.gov)
  • PMP70 is significantly induced by administration of hypolipidemic agents in parallel with peroxisome proliferation and the induction of peroxisomal fatty acid beta-oxidation enzymes. (thermofisher.com)
  • Therapy with lipid-altering agents should be only one component of multiple risk factor intervention in individuals at significantly increased risk for atherosclerotic vascular disease due to hyperlipidemia. (nih.gov)
  • Cite this: Role of Nutriceutical Agents in Cardiovascular Diseases: An Update -- Part I - Medscape - Jul 01, 2003. (medscape.com)
  • The agents inhibited DNA and RNA synthesis in preference to protein synthesis in L1210 lymphoid leukemia cells. (nih.gov)
  • Hypolipidemic agents drug interactions: approach to establish and assess its clinical significance. (who.int)
  • The hypolipidemic effect of the combination with colestipol than that for either agent alone. (pharmru.com)
  • The amine-carboxyboranes were effective anti-inflammatory agents against septic shock, induced edema, pleurisy, and chronic arthritis at 2.5 to 8 mg/kg. (nih.gov)
  • This preparation is mostly taken as therapy of atherosclerosis for slowdown of illness progression by patients who have hypolipidemic (lipid lowering) treatment, as addition to diet (under mixed hypercholesterolemia) and so on. (7daypharmacy.net)
  • Genetic hyperlipidemic mice demonstrated the same types of reduction after treatment with the agents. (nih.gov)
  • This protein is induced by treatment with hypolipidemic agents in parallel with peroxisome proliferation and stimulation of the peroxisomal β-oxidation enzymes. (enzolifesciences.com)
  • Nicotinic acid was the first hypolipidemic agent shown to decrease the incidence of secondary myocardial infarction (MI) and reduce total mortality in MI patients. (empowerpharmacy.com)
  • It is metabolized into isoniazid, an anti-tuberculosis agent, and so is contraindicated in patients with tuberculosis. (wikipedia.org)
  • These pilot studies will seek to optimize critical elements of a full-scale randomized control trial design - the most promising study question, agent(s), target population, dosing, data collection, and appropriate outcomes. (nih.gov)
  • When primary hepatocytes were exposed to these agents, transactivation of PPARα was elevated as measured by luciferase assay. (biomedcentral.com)
  • An agent that kills microorganisms or inhibits their growth. (joyfulbelly.com)